Navigation Links
Arpida Presents Data on Iclaprim at Scientific Congress in Germany

Progress of Ongoing Programmes Confirmed

REINACH and BASEL, Switzerland, November 2 /PRNewswire-FirstCall/ -- Arpida Ltd (SWX: ARPN) presents two clinical posters on its late-stage investigational antibiotic iclaprim at the 9th annual congress for Clinical Pharmacology (Verbund Klinische Pharmakologie - VKliPha) which takes place 1-3 November in Kiel, Germany. The posters presented at the conference further expand the substantial volume of data on iclaprim that is already available. At two recent conferences in the United States, Arpida has presented a total of 24 posters on iclaprim.

Poster F-1 discusses results of Phase I studies with intravenous iclaprim in healthy volunteers. In the studies, iclaprim showed linear, predictable and gender-independent pharmacokinetic characteristics in a clinically relevant dose range. Moreover, results showed iclaprim to be safe and well-tolerated in the studies.

Poster F-25 examines the influence of ketoconazole on the pharmacokinetics and safety of intravenous iclaprim. Ketoconazole did not affect the pharmacokinetics of iclaprim. Ketoconazole is a synthetic antifungal drug used to prevent and treat skin and fungal infections, especially in immunocompromised patients. In drug-drug interaction studies, it is often used as a reference compound due to its potent inhibition of the cytochrome P450 3A4 system

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "The data presented in Kiel highlight several aspects of iclaprim's attractive profile. In these Phase I studies iclaprim's pharmacokinetics were shown to be predictable and unaffected by ketaconazole. Moreover, the good safety profile was confirmed. As at the previous ICAAC and IDSA conferences, we've encountered a lively interest in iclaprim among the congress attendees in Kiel. This again reinforces the view that there is an urgent need for new pathogen-focused antibiotics to address some of the most threatening multi-drug resistant bacteria, including MRSA. We feel iclaprim could in the future play an important role in combating life-threatening infections caused by 'the superbug'."

The Phase I data presented in Kiel will be part of the NDA package that is expected to be submitted to the US Food and Drug Administration in the course of this year. Overall, the clinical programmes with iclaprim and the path towards the NDA filing for intravenous iclaprim in its first indication are on track. Patient enrolment into the Phase II studies with intravenous iclaprim in its second indication (HAP/VAP/HCAP) as well as into the Phase III trial with the TLT therapy in onychomycosis is expected to get underway shortly.

Arpida has a comfortable cash position, with cash and financial investments of CHF 95 million at the end of June 2007.

Arpida plans to give further updates on the progress of intravenous and oral iclaprim as well as TLT in the course of this year.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities near Basel, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent, pathogen-focused, late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. An NDA filing is expected to take place in the second half of 2007.

In June 2007, Arpida announced that it has received approval from the US FDA to initiate Phase II trials with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

An oral formulation of iclaprim has successfully completed three Phase I trials: an ADME study (absorption, distribution, metabolism and excretion) with radiolabelled compound, a Phase I bioavailability trial with a solution and one with a capsule formulation. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam,

President and CEO,

Tel: +41-61-417-96-60

Harry Welten, MBA,

CFO and Senior Vice President,

Tel: +41-61-417-96-65

Paul Verbraeken,

Head of Corporate Communications,

Tel: +41-61-417-96-83

SOURCE Arpida Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. NimbleGen presents new tech for comparing microbe DNA
2. Wisconsin Technology Network presents symposium on saving lives by the use of Information Technology
3. Thieme Presents Unique Technology Angle at Gov.s Conference
4. UW-Madisons Beebe wins scientific award
5. Researchers say scientific reporting needs more perspective, less hype
6. Wisconsin stands at the center of scientific efforts to avert flu epidemics
7. Growth prompts new location for scientific instrument manufacturer
8. UW stem cell guru outlines scientific and political future
9. Wisconsin biotech sector featured in scientific magazine
10. Scientific Protein Laboratories Acquired by New York firm
11. GenTel Appoints Burke to its Scientific Advisory Board
Post Your Comments:
(Date:10/8/2015)... , Oct. 8, 2015 Celemics, a global ... into the North American market with the establishment of ... and Europe , has secured ... Target Enrichment methodology and sample preparation for DNA sequencing ... both hereditary and somatic genetic testing more accurately, quickly, ...
(Date:10/8/2015)... Global Biologics and Biosimilars ... Biosimilars industry . --> Big Market ... Industry 2015 Deep Market Research Report, Size, Share, ... and depth research report on Global Biologics ... , --> ) , ...
(Date:10/8/2015)... Oct. 8, 2015  Today, DuPont and Caribou ... genome editing, jointly announced a strategic alliance. As ... their respective patent portfolios, with DuPont receiving exclusive ... major row crops, and non-exclusive rights in other ... --> --> In addition, ...
(Date:10/8/2015)... Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical ... autologous cell therapies, today announced its schedule of upcoming presentations ... month of October: Stem Cell Meeting on ... presenting at the annual Partnering Forum, part of the ... October 7-9 in La Jolla, California ...
Breaking Biology Technology:
... form of skin cancer, afflicts more than 50,000 people in ... rise. In a study published online in Genome ... ever before into the RNA world of the melanoma tumor ... the disease. The latest high-throughput DNA sequencing ...
... ... ... ... ...
... ... report on Fermenters market. The US market for fermenters is projected to reach $180 million ... biological drugs worldwide, and growing use of disposable or single-use fermenters. , ... San Jose, California (PRWEB) February 22, 2010 -- ...
Cached Biology Technology:
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
Breaking Biology News(10 mins):
... that the clouded leopard found on the islands of Borneo ... secretive rainforest animal was originally thought to be the same ... , Genetic analysis conducted at the U.S. National Cancer ... species is comparable to the differences between other large cat ...
... Professor of Medicine and Pharmacology at the University of ... about 265 twin pairs over the past few years, ... "By studying many traits and genes, we have started ... Studying genetic variations in twins provides scientists with data ...
... in stem cell research may mean big things for cancer ... research team at the University of Kentucky published their findings ... The researchers genetically mapped a stem cell gene and its ... investigation all the way through to the identification of the ...
Cached Biology News:
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... The GenElute Gel Extraction Kit combines silica- binding ... vacuum column format. DNA fragments of interest are ... solubilizing the gel. The Gel Solubilization Solution can ... in either TBE or TAE buffer. Extracted DNA ...
... are designed for the rapid purification of linear ... gels. The DNA band is excised from an,agarose ... within the base of the column are a ... and impurities back while allowing DNA to selectively ...
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
Biology Products: